Timothy A. Chan, MD, PhD

Radiation Oncologist

PaineWebber Chair in Cancer Genetics; Director, Immunogenomics and Precision Oncology Platform; Member, Human Oncology & Pathogenesis Program; Vice Chair, Department of Radiation Oncology; Director, Translational Oncology Division

Timothy A. Chan, MD, PhD

About Me

I am Vice Chair of the Department of Radiation Oncology and Director of the Division of Translational Oncology. I am a board-certified radiation oncologist with a special interest in treating patients with brain tumors. I specialize in the use of stereotactic radiosurgery, intensity-modulated radiation therapy (IMRT), and conformal radiation therapy to treat both benign and malignant brain tumors precisely and effectively, while minimizing the effects of treatment on nearby healthy tissue. Among the diseases I treat are acoustic neuroma, meningioma, glioblastoma, anaplastic astrocytoma, low-grade glioma, oligodendroglioma, pituitary adenoma, and ependymoma.

Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

I am a member of Memorial Sloan Kettering’s central nervous system disease management team, and I work closely with neurosurgeons and neuro-oncologists to provide optimal care for our patients. I am also a member of the Brain Tumor Center.

In addition to caring for patients, I am the principal investigator of a cancer genetics laboratory in the Human Oncology and Pathogenesis Program, where my colleagues and I are exploring the genetic changes that lead to cancer. We are dedicated to using our findings on the cancer genome to develop better diagnostic and treatment approaches that will improve the care of people with cancer.

  • Clinical Expertise: Malignant and Benign Brain Tumors (Meningiomas, Glioblastomas [Gliomas], Anaplastic Astrocytomas, Low-grade Gliomas, Oligodendrogliomas, Ependymomas); Acoustic Neuromas; Pituitary Tumors; Stereotactic Radiosurgery; Intensity-Modulated Radiation Therapy (IMRT); 3D Conformal Radiation Therapy
  • Languages Spoken: English
  • Education: MD, Johns Hopkins School of Medicine
  • Residencies: Radiation Oncology - Johns Hopkins Hospital
  • Fellowships: Tumor Biology - Johns Hopkins Cancer Center
  • Board Certifications: Radiation Oncology

My Research

View my lab

See Timothy A. Chan’s laboratory
research at Memorial Sloan Kettering.


Chan TA, Weingart JD, Parisi M, Hughes MA, Olivi A, Borzillary S, Alahakone D, Detorie NA, Wharam MD, Kleinberg L.. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.. Int J Radiat Oncol Biol Phys July 15, 2005; 62(4) :1133-9

Chan, TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention.. Lancet Oncology March 2002; 3(3) :166-74

Chan TA, Wang Z, Dang LH, Vogelstein B, Kinzler KW. . Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proc Natl Acad Sci USA. June 11, 2002; 99(12) :8265-70

Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

Clinical Trials

As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.

Learn more


Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.

Learn more